Detection of a novel pathogenic variant in KCNH2 associated with long QT syndrome 2 using whole exome sequencing.


Journal

BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628

Informations de publication

Date de publication:
07 May 2024
Historique:
received: 20 01 2024
accepted: 02 05 2024
medline: 8 5 2024
pubmed: 8 5 2024
entrez: 7 5 2024
Statut: epublish

Résumé

Long QT syndrome (LQTS) is a cardiac channelopathy characterized by impaired myocardial repolarization that predisposes to life-threatening arrhythmias. This study aimed to elucidate the genetic basis of LQTS in an affected Iranian family using whole exome sequencing (WES). A 37-year-old woman with a personal and family history of sudden cardiac arrest and LQTS was referred for genetic study after losing her teenage daughter due to sudden cardiac death (SCD). WES was performed and variants were filtered and prioritized based on quality, allele frequency, pathogenicity predictions, and conservation scores. Sanger sequencing confirmed segregation in the family. WES identified a novel heterozygous frameshift variant (NM_000238.4:c.3257_3258insG; pGly1087Trpfs*32) in the KCNH2 encoding the α-subunit of the rapid delayed rectifier potassium channel responsible for cardiac repolarization. This variant, predicted to cause a truncated protein, is located in the C-terminal region of the channel and was classified as likely pathogenic based on ACMG guidelines. The variant was absent in population databases and unaffected family members. This study reports a novel KCNH2 frameshift variant in an Iranian family with LQTS, expanding the spectrum of disease-causing variants in this gene. Our findings highlight the importance of the C-terminal region in KCNH2 for proper channel function and the utility of WES in identifying rare variants in genetically heterogeneous disorders like LQTS. Functional characterization of this variant is warranted to fully elucidate its pathogenic mechanisms and inform personalized management strategies.

Sections du résumé

BACKGROUND BACKGROUND
Long QT syndrome (LQTS) is a cardiac channelopathy characterized by impaired myocardial repolarization that predisposes to life-threatening arrhythmias. This study aimed to elucidate the genetic basis of LQTS in an affected Iranian family using whole exome sequencing (WES).
METHODS METHODS
A 37-year-old woman with a personal and family history of sudden cardiac arrest and LQTS was referred for genetic study after losing her teenage daughter due to sudden cardiac death (SCD). WES was performed and variants were filtered and prioritized based on quality, allele frequency, pathogenicity predictions, and conservation scores. Sanger sequencing confirmed segregation in the family.
RESULTS RESULTS
WES identified a novel heterozygous frameshift variant (NM_000238.4:c.3257_3258insG; pGly1087Trpfs*32) in the KCNH2 encoding the α-subunit of the rapid delayed rectifier potassium channel responsible for cardiac repolarization. This variant, predicted to cause a truncated protein, is located in the C-terminal region of the channel and was classified as likely pathogenic based on ACMG guidelines. The variant was absent in population databases and unaffected family members.
CONCLUSION CONCLUSIONS
This study reports a novel KCNH2 frameshift variant in an Iranian family with LQTS, expanding the spectrum of disease-causing variants in this gene. Our findings highlight the importance of the C-terminal region in KCNH2 for proper channel function and the utility of WES in identifying rare variants in genetically heterogeneous disorders like LQTS. Functional characterization of this variant is warranted to fully elucidate its pathogenic mechanisms and inform personalized management strategies.

Identifiants

pubmed: 38715010
doi: 10.1186/s12920-024-01900-z
pii: 10.1186/s12920-024-01900-z
doi:

Substances chimiques

ERG1 Potassium Channel 0
KCNH2 protein, human 0

Types de publication

Journal Article Case Reports Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

126

Informations de copyright

© 2024. The Author(s).

Références

Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. ScientificWorldJournal. 2012;2012:212178.
doi: 10.1100/2012/212178 pubmed: 22593664 pmcid: 3347892
Giray D, Donmez YN, Epcacan S, Goktas E. A rare coincidence: the long QT syndrome and cardio-facio-cutaneous syndrome. Cardiol Young. 2020;30(8):1209–11.
doi: 10.1017/S1047951120001808 pubmed: 32635955
Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120(18):1761–7.
doi: 10.1161/CIRCULATIONAHA.109.863209 pubmed: 19841298 pmcid: 2784143
Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, et al. Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med. 1998;339(14):960–5.
doi: 10.1056/NEJM199810013391404 pubmed: 9753711
Adkison LR. Elsevier’s Integrated Review Genetics E-Book: with STUDENT CONSULT Online Access. 2011.
Amin AS, Pinto YM, Wilde AA. Long QT syndrome: beyond the causal mutation. J Physiol. 2013;591(17):4125–39.
doi: 10.1113/jphysiol.2013.254920 pubmed: 23753525 pmcid: 3779107
Kim WC, Lemire E, Nosib S, Nosib SA, Novel Frameshift, Mutation. KCNH2 [p.Asp896ArgfsX79], leading to malignant ventricular arrhythmia, identified after treatment of gastrointestinal bleeding. CJC Open. 2021;3(11):1383–7.
doi: 10.1016/j.cjco.2021.06.005 pubmed: 34901807 pmcid: 8640589
Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–22.
doi: 10.1056/NEJMra032426 pubmed: 14999113
Aydar E, Palmer C. Functional characterization of the C-terminus of the human ether-à-go-go-related gene K(+) channel (HERG). J Physiol. 2001;534(Pt 1):1–14.
doi: 10.1111/j.1469-7793.2001.t01-3-00001.x pubmed: 11432987 pmcid: 2278693
Ono M, Burgess DE, Schroder EA, Elayi CS, Anderson CL, January CT, et al. Long QT syndrome type 2: emerging strategies for correcting class 2 KCNH2 (hERG) mutations and identifying new patients. Biomolecules. 2020;10(8):1144.
doi: 10.3390/biom10081144 pubmed: 32759882 pmcid: 7464307
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.
doi: 10.1038/gim.2015.30 pubmed: 25741868 pmcid: 4544753
Hille B. Potassium channels and chloride channels. In Ionic Channels of Excitable Membrane. Edited by Hill B. 1992:130-3.
Wang W, MacKinnon R. Cryo-EM structure of the Open Human Ether-a-go-go-related K(+) Channel hERG. Cell. 2017;169(3):422–30. e10.
doi: 10.1016/j.cell.2017.03.048 pubmed: 28431243 pmcid: 5484391
De Zio R, Gerbino A, Forleo C, Pepe M, Milano S, Favale S, et al. Functional study of a KCNH2 mutant: novel insights on the pathogenesis of the LQT2 syndrome. J Cell Mol Med. 2019;23(9):6331–42.
doi: 10.1111/jcmm.14521 pubmed: 31361068 pmcid: 6714209
Neyroud N, Richard P, Vignier N, Donger C, Denjoy I, Demay L, et al. Genomic organization of the KCNQ1 K + channel gene and identification of C-terminal mutations in the long-QT syndrome. Circ Res. 1999;84(3):290–7.
doi: 10.1161/01.RES.84.3.290 pubmed: 10024302
Chen J, Zou A, Splawski I, Keating MT, Sanguinetti MC. Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation. J Biol Chem. 1999;274(15):10113–8.
doi: 10.1074/jbc.274.15.10113 pubmed: 10187793
Jenke M, Sanchez A, Monje F, Stuhmer W, Weseloh RM, Pardo LA. C-terminal domains implicated in the functional surface expression of potassium channels. EMBO J. 2003;22(3):395–403.
doi: 10.1093/emboj/cdg035 pubmed: 12554641 pmcid: 140720
Kupershmidt S, Snyders DJ, Raes A, Roden DM. A K + channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current. J Biol Chem. 1998;273(42):27231–5.
doi: 10.1074/jbc.273.42.27231 pubmed: 9765245
Kupershmidt S, Yang T, Chanthaphaychith S, Wang Z, Towbin JA, Roden DM. Defective human ether-a-go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus. J Biol Chem. 2002;277(30):27442–8.
doi: 10.1074/jbc.M112375200 pubmed: 12021266
Nakajima T, Furukawa T, Hirano Y, Tanaka T, Sakurada H, Takahashi T, et al. Voltage-shift of the current activation in HERG S4 mutation (R534C) in LQT2. Cardiovasc Res. 1999;44(2):283–93.
doi: 10.1016/S0008-6363(99)00195-9 pubmed: 10690305
Sasano T, Ueda K, Orikabe M, Hirano Y, Kawano S, Yasunami M, et al. Novel C-terminus frameshift mutation, 1122 fs/147, of HERG in LQT2: additional amino acids generated by frameshift cause accelerated inactivation. J Mol Cell Cardiol. 2004;37(6):1205–11.
doi: 10.1016/j.yjmcc.2004.09.010 pubmed: 15572050
Zhou Z, Gong Q, Epstein ML, January CT. HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. J Biol Chem. 1998;273(33):21061–6.
doi: 10.1074/jbc.273.33.21061 pubmed: 9694858
Paulussen AD, Raes A, Jongbloed RJ, Gilissen RA, Wilde AA, Snyders DJ, et al. HERG mutation predicts short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency. Cardiovascular Res. 2005;67(3):467–75.
doi: 10.1016/j.cardiores.2005.05.017
Puckerin A, Aromolaran KA, Chang DD, Zukin RS, Colecraft HM, Boutjdir M, et al. hERG 1a LQT2 C-terminus truncation mutants display hERG 1b-dependent dominant negative mechanisms. Heart Rhythm. 2016;13(5):1121–30.
doi: 10.1016/j.hrthm.2016.01.012 pubmed: 26775140
Choe C-u, Schulze-Bahr E, Neu A, Xu J, Zhu ZI, Sauter K, et al. C-terminal HERG (LQT2) mutations disrupt I kr channel regulation through 14-3-3ϵ. Hum Mol Genet. 2006;15(19):2888–902.
doi: 10.1093/hmg/ddl230 pubmed: 16923798

Auteurs

Erfan Kohansal (E)

Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

Niloofar Naderi (N)

Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

Amir Farjam Fazelifar (AF)

Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

Majid Maleki (M)

Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

Samira Kalayinia (S)

Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. samira.kalayi@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH